Literature DB >> 12097164

Ligation of human CD46 with purified complement C3b or F(ab')(2) of monoclonal antibodies enhances isoform-specific interferon gamma-dependent nitric oxide production in macrophages.

Akiko Hirano1, Mitsue Kurita-Taniguchi, Yuko Katayama, Misako Matsumoto, Timocy C Wong, Tsukasa Seya.   

Abstract

CD46, a complement regulatory protein widely expressed on human cells, serves as an entry receptor for measles virus (MV). We have previously shown that the expression of human CD46 in mouse macrophages restricts MV replication in these cells and enhances the production of nitric oxide (NO) in the presence of gamma interferon (IFN-gamma). In this study, we show that crosslinking human CD46 expressed on the mouse macrophage-like cell line RAW264.7 with purified C3b multimer but not monomer enhances NO production. The enhanced production of NO in response to IFN-gamma was observed again with C3b multimer but not monomer. The augmentation of NO production is human CD46-dependent with a CYT1>CYT2 profile. Thus, the reported MV-mediated NO production, irrespective of whether it is IFN-gamma-dependent or -independent, should be largely attributable to CD46 signaling but not to MV replication. Similar CYT1-dependent augmentation of NO production was reproducible with two CD46 ligating reagents, CD46-specific monoclonal antibodies (mAb) or their F(ab')(2) and MV hemagglutinin (H) and fusion (F) glycoproteins. Co-cultivation of mouse macrophages bearing human CD46 with Chinese hamster ovary (CHO) cells expressing MV H and F enhanced IFN-gamma-induced NO production. Yet, the NO levels induced by F(ab')(2) against CD46 or MV H/F on CHO cells were much lower than those induced by CD46-crosslinking mAb with Fc or MV infection. Removing the cytoplasmic tails of CD46 abrogated the augmentation of NO production triggered by all three stimulators. Thus, the CD46 CYT1 and CYT2 isoforms functionally diverge to elicit innate immune responses, which can be modulated by purified C3b multimer or anti-CD46 mAbs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12097164     DOI: 10.1093/oxfordjournals.jbchem.a003203

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  7 in total

Review 1.  T-cell stimulation and regulation: with complements from CD46.

Authors:  Claudia Kemper; James W Verbsky; Jeffrey D Price; John P Atkinson
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  Inhibition of CXCL10 release by monomeric C3bi and C4b.

Authors:  Y Takeda; K Kaneda; F Jimma; N Shiobara; M Hidaka; A R Saniabadi; I Wakabayashi
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

3.  Presenilin/gamma-secretase cleaves CD46 in response to Neisseria infection.

Authors:  Nathan J Weyand; Christine M Calton; Dustin L Higashi; Kristen J Kanack; Magdalene So
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

Review 4.  T-cell regulation by CD46 and its relevance in multiple sclerosis.

Authors:  Anne L Astier
Journal:  Immunology       Date:  2008-04-02       Impact factor: 7.397

5.  Monoclonal antibody detection of CD46 clustering beneath Neisseria gonorrhoeae microcolonies.

Authors:  Nathan J Weyand; Shaun W Lee; Dustin L Higashi; Daniel Cawley; Paul Yoshihara; Magdalene So
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

6.  The HSP GRP94 interacts with macrophage intracellular complement C3 and impacts M2 profile during ER stress.

Authors:  Killian Chaumonnot; Sophie Masson; Hugo Sikner; Alexanne Bouchard; Valentin Baverel; Pierre-Simon Bellaye; Bertrand Collin; Carmen Garrido; Evelyne Kohli
Journal:  Cell Death Dis       Date:  2021-01-22       Impact factor: 8.469

7.  CD46 Genetic Variability and HIV-1 Infection Susceptibility.

Authors:  Carmen Serrano-Rísquez; Mohamed Omar; María Amparo Gómez-Vidal; Luis Miguel Real; Juan Antonio Pineda; Antonio Rivero; Antonio Rivero-Juárez; Donald Forthal; Francisco J Márquez; Sergio Lo Caputo; Mario Clerici; Mara Biasin; Antonio Caruz
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.